...
Code Block |
---|
MSH|^~\&|MOADLEDIT^MOADLEDIT:3.1.2 (Build 6381) [win32-i386]^L|Unassigned^8D9FE669-4710-455D-8B97-811508B616E7^GUID|||2016110215051420161019162427+1100||ORU^R01^ORU_R01|XX11021505120XX10191624300-78594735|P|2.4^AUS&Australia&ISO3166_1^HL7AU-OO-201701&&L|||AL|AL|AUS||en^English^ISO639 PID|1||8003608833357361^^^AUSHIC^NI~7654321^^^RMH^MR||CITIZEN^GEORGE||19640701|M|||C/o Paradise Close^^NAR NAR GOON^VIC^3812^AUGOON^VIC^3812^AUS PV1|1|O|||||||419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN ORC|RE||3BE7CECB92D0CE50-AD59173A-4C464A2F-B711A3B1-5F6E137C2890^Unassigned^8D9FE6696165376F222B^Unassigned^8D9FE669-4710-455D-8B97-811508B616E7^GUID||CM|||||||419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN OBR|1||3BE7CECB92D0CE50-AD59173A-4C464A2F-B711A3B1-5F6E137C2890^Unassigned^8D9FE6696165376F222B^Unassigned^8D9FE669-4710-455D-8B97-811508B616E7^GUID|8490784908-5^Colorectal3^Prostate Cancer Structured Pathology Report^LNHistopathology^LN||20161019+1100|2016110220161019+1100|||||||||419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN||||LN=3BE7CECB92D0CE50-AD59173A-4C464A2F-B711A3B1-5F6E137C28906165376F222B||201611021450201610191609+1100||SPPHY|F||^^^20161102^^^20161019+1100|419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN~921198YF^SMITH^MICHAEL^^^DR^^^AUSHICPR^L^^^UPIN OBX|1|RP|60572-5^^LN^ENTRY^^EN 13606|1|CEN.RCPA-ColorectalCancer.v3^ColorectalProstateCancer_(Rad_Prostatectomy).v2^Prostate Cancer Structured Pathology ReportHistopathology&99A-4DD10FEE7661CBF6F4ADB3A91A896333&L^TEXT^OctetL^TX^Octet-stream||||||F OBX|2|CE|70949-3^^LN^CLUSTER^^EN 13606|1.1|70949-3^Clinical details^LN||||||F OBX|3|ST|5575229306-0^Clinical8^Surgical information^LNprocedure^LN|1.1.12|RRadical Colon cancerprostatectomy||||||F OBX|4|ST|5772355752-9^Pathology0^Clinical Accession number^LNinformation^LN|1.1.2|89671-16MP4|PCa G6 - prostate and seminal vesicles - left and right pelvic nodes - pre-prostatic fat - left apical margin - left lateral margin||||||F OBX|5|STNM|220272857-1^Pre-7^Operatingbiopsy surgeonserum name^LNPSA^LN|1.1.3|Dr Dayoub|6|5.9|ug/L^^ISO+|||||F OBX|6|CEST|33725-3^Tumour location^LNLN-RCPA-00085^Relevant clinical information for clinicopathological staging^L|1.1.7|32713005^Caecum^SCT8|Core biopsy Gleason score: 3+3=6||||||F OBX|7|CEST|2930657723-8^Type9^Pathology ofaccession operation^LNnumber^LN|1.1.10|235326000^Right hemicolectomy^SCT9|89470-15MP||||||F OBX|8|ST|8116918600-5^Surgeon's opinion on the existence of local residual cancer postsurgery^LN7^Principal clinician^LN|1.1.1310|NotDr statedSmith||||||F OBX|9|STCE|LN70949-RCPA-00064^Involvement of adjacent organs^LN3^^LN^CLUSTER^^EN 13606|1.1.14|Not stated2|70949-3^Macroscopic findings^LN||||||F OBX|10|STNM|LN29638-RCPA-00065^Regional (local) recurrence or distant metastasis^LN|1.1.16|Not stated|4^Specimen weight^LN|1.2.1|60|g^^ISO+|||||F OBX|11|CE|70949-3^^LN^CLUSTER^^EN 13606|1.2.2|70949-3^Macroscopic findings^LNLN-RCPA-00086^Specimen dimensions (prostate)^L||||||F OBX|12|NM|LN-RCPA-00066^Specimen length^LN00100^Length^L|1.2.2.1|11351|mm^^ISO+|||||F OBX|13|CENM|33725-3^Tumour site^LNLN-RCPA-00101^Width^L|1.2.2.2|32713005^Caecum^SCT47|mm^^ISO+|||||F OBX|14|NM|21889-1^Maximum tumour diameter^LNLN-RCPA-00102^Thickness^L|1.2.2.3|4342|mm^^ISO+|||||F OBX|15|NMCE|81175LN-RCPA-2^Distance of tumour to the nearer proximal or distal 'cut end'^LN00087^Seminal vesicles^L|1.2.3|at0196^Present^99A-F4ADB3A91A896333||||||F OBX|16|CE|LN-RCPA-00088^Lymph nodes^L|1.2.4|3552101004^Present^SCT|mm^^ISO+|||||F OBX|1617|NMCE|LN-RCPA-00067^Distance to nonperitonealised circumferential margin^LN20228-3^Laterality^LN|1.2.5|3551440002^Bilateral^SCT|mm^^ISO+|||||F OBX|1718|CE|LN70949-RCPA-00068^Tumour3^^LN^CLUSTER^^EN perforation^LN13606|1.2.6|2667000^Absent^SCT.1|at0024^Site(s) and numbers of lymph nodes^99A-F4ADB3A91A896333||||||F OBX|1819|CEST|LN-RCPA-00069^Relationship to anterior peritoneal reflection^LN39111-0^Site^LN|1.2.6.1.71|at0092^Entirely above^99A-4DD10FEE7661CBF6|Left pelvic||||||F OBX|1920|CENM|66112-4^Lymph nodes^LN21894-1^Number of LNs from this site^LN|1.2.6.1.102|at0224^Received^99A-4DD10FEE7661CBF61||||||F OBX|2021|CEST|7094939111-3^^LN^CLUSTER^^EN0^Site 13606|2^LN|1.2.6.1.3|70949-3^MicroscopicRight findings^LNpelvic||||||F OBX|2122|CENM|LN-RCPA-00071^Tumour type^LN|1.3.1|35917007^Adenocarcinoma, NOS^SCT21894-1^Number of LNs from this site^LN|1.2.6.1.4|1||||||F OBX|2223|CEST|33732-9^Histological grade^LN22634-0^Additional macroscopic comments^LN|1.32.28|399415002^Low grade - well and moderately differentiated^SCTVolume: 0.6cm3 (3D volume estimate method)||||||F OBX|2324|CE|LN70949-RCPA-00072^Maximum degree of local invasion into or through the bowel wall^LN|1.33^^LN^CLUSTER^^EN 13606|1.3|395707006^pT370949-Tumour invades through muscularis propria into pericolorectal tissues^SCT3^Microscopic findings^LN||||||F OBX|2425|CE|LN44639-RCPA-00073^Involvement3^Histological of the proximal/distal resection ('cut end') margins^LNtumour type^LN|1.3.4|at0143^Not involved^99A-4DD10FEE7661CBF61|45410002^Adenocarcinoma (Acinar, usual type)^SCT||||||F OBX|2526|CE|LN70949-RCPA-00075^Status of nonperitonealised circumferential margin (rectal tumours)^LN|1.3.8|at0241^Not involved^99A-4DD10FEE7661CBF63^^LN^CLUSTER^^EN 13606|1.3.4|at0093^Tumour location^99A-F4ADB3A91A896333||||||F OBX|2627|NMCE|LN70949-RCPA-00076^Microscopic3^^LN^CLUSTER^^EN clearance^LN13606|1.3.9|35|mm^^ISO+4.4|LN-RCPA-00092^Locations by quadrant^L||||||F OBX|2728|CE|70949-3^^LN^CLUSTER^^EN264176005^Right 13606anterior^SCT|1.3.114.4.1|70949-3^Lymph node site/s^LN31874001^Yes^SCT||||||F OBX|2829|STCE|21893-3^Number of positive^LN277593009^Right posterior^SCT|1.3.114.14.2|031874001^Yes^SCT||||||F OBX|2930|STCE|21894-1^Total number of lymph nodes^LN264065008^Left anterior^SCT|1.3.114.14.3|1331874001^Yes^SCT||||||F OBX|3031|CE|LN-RCPA-00077^Isolated extra-mural tumour deposits^LN277594003^Left posterior^SCT|1.3.12|2667000^Absent^SCT4.4.4|31874001^Yes^SCT||||||F OBX|3132|CE|LN70949-RCPA-00078^Apical node involvement^LN3^^LN^CLUSTER^^EN 13606|1.3.13|2667000^Absent^SCT4.5|LN-RCPA-00090^Locations by plane^L||||||F OBX|3233|CE|70949-3^^LN^CLUSTER^^EN 1360668756004^Apex^SCT|1.3.14|70949-3^Venous and small vessel invasion^LN4.5.1|64100000^No^SCT||||||F OBX|3334|CE|LN-RCPA-00079^Intramural vein invasion^LN279704000^Mid^SCT|1.3.144.5.2|at0146^Not identified^99A-4DD10FEE7661CBF664100000^No^SCT||||||F OBX|3435|CE|LN-RCPA-00080^Extramural vein invasion^LN36082003^Base of prostate^SCT|1.3.4.145.3|at0149^Not identified^99A-4DD10FEE7661CBF6|64100000^No^SCT||||||F OBX|3536|CE|3373970949-4^Small3^^LN^CLUSTER^^EN vessel invasion^LN13606|1.3.14.4|372265000^Present^SCT7|372278000^Histological tumour grade^SCT||||||F OBX|3637|CENM|3374144641-0^Perineural9^Primary Gleason invasion^LNgrade^LN|1.3.7.15|at0156^Not identified^99A-4DD10FEE7661CBF61|3||||||F OBX|3738|CENM|LN44642-RCPA-00081^Histologically7^Secondary confirmedGleason distant metastases^LNgrade^LN|1.3.7.162|2667000^Absent^SCT4||||||F OBX|3839|CE|81317-0^Relevant coexistant pathological abnormalities^LN385432009^Tertiary Gleason grade not applicable^SCT|1.3.18|260386005^None noted^SCT7.4|64100000^No^SCT||||||F OBX|3940|CEFT|7094935266-3^^LN^CLUSTER^^EN6^Gleason 13606score^LN^372278000^^SCT|1.3.4|70949-3^Ancillary test findings^LN||||||F OBX|40|CE|70949-3^^LN^CLUSTER^^EN 13606|1.4.1|70949-3^Mismatch repair enzymes^LN|7.5|3+4=7\.br\Composite Gleason Score (ISUP) 2005): 3+4=7 \.br\Index carcinoma score (ISUP 2005): 3+4=7 % \.br\High Grade (4/5): 5%. \.br\Intraduct carcinoma: Absent.||||||F OBX|41|CE|50328LN-4^PMSRCPA-2^LN00096^Extent^L|1.43.1.2|at0195^Normal staining^99A-4DD10FEE7661CBF69|420366008^Focal^SCT||||||F OBX|42|CE|50324-3^MSH-6^LN70949-3^^LN^CLUSTER^^EN 13606|1.43.1.4|at0201^Normal staining^99A-4DD10FEE7661CBF610|LN-RCPA-00095^Location(s) of EPE^L||||||F OBX|43|CE|43368-0^Microsatellite instablility (MSI)^LNat0138^Lateral^99A-F4ADB3A91A896333|1.43.10.1.6|373121007^Not tested^SCT64100000^No^SCT||||||F OBX|44|CE|58483-9^BRAF (V600E mutation)^LNat0139^Postero-lateral^99A-F4ADB3A91A896333|1.43.110.9|at0208^Not tested^99A-4DD10FEE7661CBF62|64100000^No^SCT||||||F OBX|45|CE|21703-4^RAS gene mutation testing^LNat0140^Posterior^99A-F4ADB3A91A896333|1.43.110.123|373121007^Not tested^SCT64100000^No^SCT||||||F OBX|46|CE|70949at0141^Anterior^99A-3^^LN^CLUSTER^^EN 13606F4ADB3A91A896333|1.3.10.5|70949-3^Synthesis and overview^LN4|64100000^No^SCT||||||F OBX|47|CE|70949-3^^LN^CLUSTER^^EN 13606at0142^Bladder neck^99A-F4ADB3A91A896333|1.3.10.5.1|21902-2^Tumour stage (AJCC 2010)^LN|64100000^No^SCT||||||F OBX|48|CE|21899at0143^Apical^99A-0^T classification^LNF4ADB3A91A896333|1.53.110.16|395707006^pT3^SCT64100000^No^SCT||||||F OBX|49|CE|21900at0144^Other^99A-6^N classification^LNF4ADB3A91A896333|1.53.110.27|at0292^pN0^L64100000^No^SCT||||||F OBX|50|CE|LN44670-RCPA-00084^Residual8^Margin tumour status^LN|1.53.2|at0212^R0^99A-4DD10FEE7661CBF611|55182004^Not involved^SCT||||||F OBX|51|FTCE|2263744626-3^Diagnostic0^Seminal summary^LNvesicles^LN|1.53.316|Diagnostic summary:\.br\Speciment type: Right hemicolectomy\.br\Tumour site: Caecal\.br\Tumour type: Adenocarcinoma\.br\Tumour stage: T3 N0 MX\.br\Completeness of excision: Completely excised\.br\Diagnosis:\.br\Right Colon - Moderately differentiated caecal Adenocarcinoma, T3\.br\Thirteen lymph nodes negative for metastatis (0/13)\.br\Surgical margins clearat0160^Not involved^99A-F4ADB3A91A896333||||||F OBX|52|CE|70949-3^^LN^CLUSTER^^EN 13606|1.3.19|23.02.28965^Lymph node status^RCPA||||||F OBX|53|NM|44621-1^Number of lymph nodes examined^LN|1.3.19.1|1||||||F OBX|54|NM|21893-3^Number of positive lymph nodes^LN|1.3.19.2|0||||||F |
...
OBX|55|CE|59544-7^Lymphovascular invasion^LN|1.3.20|at0171^Not identified^99A-F4ADB3A91A896333||||||F OBX|56|CE|70949-3^^LN^CLUSTER^^EN 13606|1.4|70949-3^Synthesis and overview^LN||||||F OBX|57|CE|70949-3^^LN^CLUSTER^^EN 13606|1.4.1|21902-2^Pathological staging (AJCC 7th Ed)^LN||||||F OBX| |
...
58| |
...
CE| |
...
21899-0^Primary tumour (T)^LN|1.4.1.1|at0176^T2 Organ Confined^L||||||F OBX| |
...
59| |
...
CE| |
...
70949-3^^LN^CLUSTER^^EN 13606|1.4.2|67203-0^Year and edition of staging system^LN||||||F
OBX|60|ST|at0106^Year^99A-F4ADB3A91A896333|1.4.2.1|AJCC 2005||||||F
OBX|61|ST|at0107^Edition^99A-F4ADB3A91A896333|1.4.2.2|7th Ed||||||F
OBX|62|FT|34574-4^Diagnostic summary^LN|1.4.3|1. Radical prostatectomy: Prostatic adenocarcinoma \.br\2. Left pelvic lymph node: Fibradipose tissue only \.br\3. Right pelvic lymph node: No evidence of malignancy \.br\4. Periprostatic tissue: No evidence of malignancy \.br\5. Left apical margin: No evidence of mailgnancy 6. Left lateral margin: No evidence of malignancy||||||F
OBX|63|ED|PDF^Display format in PDF^AUSPDI||ECLIPSE&ECLIPSE:3.1.8 [win32-i386]&L^application^pdf^Base64^JVB...UlRU9GDQo=||||||F
|